Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Five-Month Follow-up Shows No Improvement in Dermatological Complications in Children With Type 1 Diabetes Using Continuous Glucose Monitoring Systems and Insulin Pumps

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. A New Medical Device for Improved Rotation of Insulin Injections in Type 1 Diabetes Mellitus: A Proof-of-Concept Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Telemedicine Consultations and Diabetes Technology During COVID-19

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  3. Feasibility of a New Approach to Initiate Insulin in Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. No immediate effect of regulatory reduction of chromium in leather among adult patients with chromium allergy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Safety of the combined use of methotrexate and acitretin in a dermatology hospital setting

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  3. Characterization of the Oral and Gut Microbiota in Patients with Psoriatic Diseases: A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

BACKGROUND: A Danish study showed that 90% of the pediatric patients who participated had some time experienced dermatological complications due to treatment with continuous subcutaneous insulin infusion (CSII). This follow-up study describes dermatological complications due to CSII and/or continuous glucose monitoring (CGM) between the two study periods and includes health-related quality of life (HrQoL) measurements.

METHODS: A total of 138 patients (95%) out of 145 patients from the initial study answered an online questionnaire regarding dermatological complications related to CSII and/or CGM, five months later. A second questionnaire (DISABKIDS) regarding HrQoL was sent out to those 138 of which 111 patients completed it. The patients were aged from 2 to 20 years. Descriptive statistics, χ2 tests, and univariate and multivariate analyses were used to analyze the data.

RESULTS: In total, 81% of the 138 patients continued to have dermatological complications at follow-up. Itching was the most frequently reported complication. Patients using Enlite reported more dermatological complications than those using Libre. In total, 79% of the patients who used barrier cream in the initial study still had dermatological complications five months later. Age, gender, Body Mass Index (BMI), or HbA1c levels showed no significant association with dermatological complications. Patients who perceived dermatological complications as a greater problem had lower HrQoL scores.

CONCLUSION: Once dermatological complications start to appear, they become chronic, indicating that the treatments currently available are inadequate. Patients perceiving dermatological complications as a greater problem were associated with lower HrQoL. These findings highlight the need for additional preventive studies.

OriginalsprogEngelsk
TidsskriftJournal of diabetes science and technology
Vol/bind15
Udgave nummer2
Sider (fra-til)317-323
Antal sider7
ISSN1932-2968
DOI
StatusUdgivet - mar. 2021

ID: 59237575